4.6 Review

Orthopedia Homeobox (OTP) in Pulmonary Neuroendocrine Tumors: The Diagnostic Value and Possible Molecular Interactions

Journal

CANCERS
Volume 11, Issue 10, Pages -

Publisher

MDPI
DOI: 10.3390/cancers11101508

Keywords

orthopedia homeobox; pulmonary carcinoid; neuroendocrine tumor; prognosis; classification; review

Categories

Funding

  1. KWF kankerbestrijding [10956]

Ask authors/readers for more resources

Generally, patients with stage I-IIIa (TNM) pulmonary carcinoid disease have a favourable prognosis after curative resection. Yet, distant recurrence of disease after curative surgery occurs in approximately 1-6% of patients with typical carcinoid and 14-29% in patients with atypical carcinoid disease, respectively. Known predictors of distant recurrence of disease are atypical carcinoid, lymphatic involvement, and incomplete resection status. However, none of them can be reliably used, alone or in combination, to exclude patients from long-term follow-up (advised 15 years). By genomic profiling, Orthopedia homeobox (OTP) has been identified as a promising prognostic marker for pulmonary carcinoid with a favourable prognosis and low risk of distant disease recurrence. Moreover, OTP is a highly specific marker for carcinoids of pulmonary origin and recent genome wide analysis has identified OTP as a crucial predictor of aggressive tumor behaviour. OTP in combination with CD44, a stem cell marker and cell-surface protein, enables the identification of patients with surgical resected carcinoid disease that could potentially be excluded from long-term follow-up. In future clinical practice OTP may enable clinicians to reduce the diagnostic burden and related distress and reduce costs of long-term radiological assessments in patients with a pulmonary carcinoid. This review addresses the current clinical value of OTP and the possible molecular mechanisms regulating OTP expression and function in pulmonary carcinoids.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial

Nikki de Rouw, Rene J. Boosman, Jacobus A. Burgers, Alwin D. R. Huitema, Anne-Marie C. Dingemans, Hieronymus J. Derijks, David M. Burger, Berber Piet, Lizza E. L. Hendriks, Bonne Biesma, Melinda A. Pruis, Daphne W. Dumoulin, Sander Croes, Ron H. J. Mathijssen, Michel M. van den Heuvel, Rob ter Heine

Summary: This study compared optimized dosing of pemetrexed to standard body surface area-based dosing in patients with non-small cell lung cancer and mesothelioma. The results showed no superiority of optimized dosing in terms of pharmacokinetic endpoint, safety, or quality of life.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2023)

Article Oncology

Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial

J. Remon, B. Besse, S. Ponce Aix, A. Callejo, K. Al-Rabi, R. Bernabe, L. Greillier, M. Majem, N. Reguart, I. Monnet, S. Cousin, P. Garrido, G. Robinet, R. Garcia Campelo, A. Madroszyk, J. Mazieres, H. Curcio, B. Wasag, Y. Pretzenbacher, B. Fournier, A. -M. C. Dingemans, R. Dziadziuszko

Summary: The APPLE trial aimed to evaluate the feasibility of longitudinal plasma EGFR T790M monitoring for the best sequencing strategy of gefitinib and osimertinib. The results showed that serial monitoring of T790M mutation in advanced EGFR-mutant non-small-cell lung cancer was feasible, and molecular progression before RECIST PD led to an earlier switch to osimertinib with satisfactory progression-free survival and overall survival outcomes.

ANNALS OF ONCOLOGY (2023)

Article Oncology

Influence of Food With Different Fat Concentrations on Alectinib Exposure : A Randomized Crossover Pharmacokinetic Trial

Daan A. C. Lanser, Simon P. de Leeuw, Esther Oomen-de Hoop, Peter de Bruijn, Marthe S. Paats, Daphne W. Dumoulin, Stijn L. W. Koolen, Anne -Marie C. Dingemans, Ron H. J. Mathijssen, Marijn Veerman

Summary: This study investigated the influence of different diets on the exposure of alectinib in ALK+ NSCLC patients. The results showed that low-fat yogurt significantly reduced the exposure of alectinib compared to other diets, while a self-chosen lunch did not change the exposure. Therefore, patients and physicians should be cautious about the food-drug interaction between alectinib and low-fat yogurt, as it may lead to reduced exposure.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2023)

Article Oncology

Analysis of Serious Weight Gain in Patients Using Alectinib for ALK-Positive Lung Cancer

Simon P. de Leeuw, Melinda A. Pruis, Barend J. Sikkema, Mostafa Mohseni, G. D. Marijn Veerman, Marthe S. Paats, Daphne W. Dumoulin, Egbert F. Smit, Annemie M. W. J. Schols, Ron H. J. Mathijssen, Elisabeth F. C. van Rossum, Anne-Marie C. Dingemans

Summary: Alectinib, a standard treatment for metastatic ALK+ NSCLC, can lead to weight gain in approximately 10% of patients. This study analyzed body composition changes in patients treated with alectinib and found increases in waist circumference, visceral adipose tissue, subcutaneous adipose tissue, and skeletal muscle. Furthermore, in-depth analysis of four patients with significant weight gain revealed increased appetite and metabolic syndrome. These findings suggest that alectinib can cause abdominal obesity and various metabolic, physical, and mental disturbances.

JOURNAL OF THORACIC ONCOLOGY (2023)

Article Medicine, General & Internal

Sotorasib versus docetaxel for previously treated non-small- cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

Adrianus Johannes de Langen, Melissa L. Johnson, Julien Mazieres, Anne -Marie C. Dingemans, Giannis Mountzios, Miklos Pless, Jurgen Wolf, Martin Schuler, Herve Lena, Ferdinandos Skoulidis, Yasuto Yoneshima, Sang-We Kim, Helena Linardou, Silvia Novello, Anthonie J. van der Wekken, Yuanbin Chen, Solange Peters, Enriqueta Felip, Benjamin J. Solomon, Suresh S. Ramalingam, Christophe Dooms, Colin R. Lindsay, Carlos Gil Ferreira, Normand Blais, Cynthia C. Obiozor, Yang Wang, Bhakti Mehta, Tracy Varrieur, Gataree Ngarmchamnanrith, Bjorn Stollenwerk, David Waterhouse, Luis Paz-Ares

Summary: This study compared the efficacy and safety of Sotorasib with standard-of-care treatment in patients with non-small-cell lung cancer (NSCLC) with the KRASG12C mutation. The results showed that compared to docetaxel, Sotorasib significantly increased progression-free survival and had a more favorable safety profile.

LANCET (2023)

Article Oncology

Prevalence and Predictors of Physician-Patient Discordance in Prognostic Perceptions in Advanced Cancer

Naomi Cornelia Anna van der Velden, Paul K. J. Han, Hanneke W. M. van Laarhoven, Filip Y. F. L. de Vos, Lizza E. L. Hendriks, Sjaak A. Burgers, Anne-Marie C. Dingemans, Jan Maarten W. van Haarst, Joyce Dits, Ellen M. A. Smets, Inge Henselmans

Summary: Discordance between physicians' and patients' prognostic perceptions in advanced cancer care threatens informed medical decision-making and end-of-life preparation, yet this phenomenon is poorly understood. This study examines the extent and predictors of physician-patient discordance in prognostic perceptions.

ONCOLOGIST (2023)

Article Oncology

Ri sk factors for cognitive impairment in radically treated stage III NSCLC : Secondary findings of the NVALT-11 study

Haiyan Zeng, Lizza E. L. Hendriks, Willem J. A. Witlox, Harry J. M. Groen, Anne-Marie C. Dingemans, John Praag, Jose Belderbos, Ruud Houben, Vincent van der Noort, Dirk K. M. De Ruysscher

Summary: The aim of this study was to identify risk factors for self-reported cognitive impairment in stage III non-small cell lung cancer (NSCLC) after radical treatment. Cognitive functioning was assessed at seven pre-specified time points using the EORTC-QLQ-C30. The results showed that baseline cognitive impairment was the most important risk factor for subsequent cognitive impairment in stage III NSCLC.

RADIOTHERAPY AND ONCOLOGY (2023)

Article Oncology

Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline

Puneeth Iyengar, Sean All, Mark F. Berry, Thomas P. Boike, Lisa Brad fi Eld, Anne -Marie C. Dingemans, Jill Feldman, Daniel R. Gomez, Paul J. Hesketh, Salma K. Jabbour, Melenda Jeter, Mirjana Josipovic, Yolande Lievens, Fiona Mcdonald, Bradford A. Perez, Umberto Ricardi, Enrico Ruffini, Dirk De Ruysscher, Hina Saeed, Bryan J. Schneider, Suresh Senan, Joachim Widder, Matthias Guckenberger

Summary: This guideline aims to review the use of local therapy in the management of extracranial oligometastatic non-small cell lung cancer (NSCLC) and provide recommendations. Currently, data is limited, but with increasing evidence supporting the use of local therapy in NSCLC, this guideline attempts to provide recommendations based on the quality of available data.

PRACTICAL RADIATION ONCOLOGY (2023)

Letter Oncology

Factors associated with long-term antibody response after COVID-19 vaccination in patients treated with systemic treatment for solid tumors

S. F. Oosting, A. A. M. van der Veldt, R. S. N. Fehrmann, A. Bhattacharya, R. S. van Binnendijk, C. H. GeurtsvanKessel, A. -M. C. Dingemans, E. F. Smit, T. J. N. Hiltermann, G. den Hartog, M. Jalving, T. T. Westphal, F. de Wilt, S. M. Ernst, A. Boerma, L. van Zijl, G. F. Rimmelzwaan, P. Kvistborg, C. A. C. M. van Els, N. Y. Rots, D. van Baarle, J. B. A. G. Haanen, E. G. E. de Vries

ESMO OPEN (2023)

Article Medicine, General & Internal

Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer

G. D. Marijn Veerman, Rene J. Boosman, Esther Oomen-de Hoop, Anthonie J. van der Wekken, Idris Bahce, Lizza E. L. Hendriks, Sander Croes, Christi M. J. Steendam, Evert de Jonge, Stijn L. W. Koolen, Neeltje Steeghs, Ron H. N. van Schaik, Egbert F. Smit, Anne-Marie C. Dingemans, Alwin D. R. Huitema, Ron H. J. Mathijssen

Summary: This study investigated the relationship between single nucleotide polymorphisms (SNPs) and the central nervous system (CNS) treatment efficacy of osimertinib in patients with EGFRm+ non-small cell lung cancer. The results showed that ABCG2 34G>A and ABCB1 3435C>T were predictors for developing new CNS metastases during osimertinib treatment. ABCG2 421C>A was significantly related to the incidence of severe toxicity.

ECLINICALMEDICINE (2023)

Letter Oncology

Approach to Alectinib- Induced Body Weight Gain in Patients With ALK plus Non-Small Lung Cancer

Anne-Marie C. Dingemans, Ron H. J. Mathijssen, Elisabeth F. C. van Rossum

JOURNAL OF THORACIC ONCOLOGY (2023)

Article Oncology

Chemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI's: Exploration of efficacy of unselected treatment in a multicenter cohort study

Christi M. J. Steendam, Sophie M. Ernst, Sushil K. Badrising, Marthe S. Paats, Joachim G. J. V. Aerts, Adrianus J. de Langen, Anne-Marie C. Dingemans

Summary: This study evaluated the efficacy of chemotherapy regimens after progression on EGFR-TKI in patients with EGFR-mutated NSCLC. The results showed substantial benefit of different chemotherapy regimens, particularly in patients treated with PP and CPBA as first-line chemotherapy, and PB in further lines of chemotherapy.

LUNG CANCER (2023)

Article Oncology

Real-world treatment patterns and survival of patients with ROS1 rearranged stage IV non-squamous NSCLC in the Netherlands

Deirdre M. H. J. ten Berge, Ronald A. M. Damhuis, Joachim G. J. V. Aerts, Anne -Marie C. Dingemans

Summary: In patients with ROS1 rearrangement in the Netherlands, only half received primary treatment with TKI and the treatment outcomes were disappointing, mainly due to brain metastasis. Therefore, performing brain MRI as part of the standard diagnostic work up in patients with ROS1+ NSCLC is crucial.

LUNG CANCER (2023)

Article Oncology

Artificial intelligence-based recurrence prediction outperforms classical histopathological methods in pulmonary adenocarcinoma biopsies

F. Akram, J. L. Wolf, T. E. Trandafir, Anne-Marie C. Dingemans, A. P. Stubbs, J. H. von der Thusen

Summary: A statistical model was developed to predict the recurrence of lung adenocarcinoma after surgical resection, and an artificial intelligence (AI) classification model based on convolutional neural networks (CNNs) was trained using transfer learning. Both models were validated using the same biopsy dataset, and the AI classification model outperformed the statistical model in predicting recurrence.

LUNG CANCER (2023)

Article Respiratory System

Differentiating interstitial lung diseases from other respiratory diseases using electronic nose technology

Iris G. van der Sar, Marlies S. Wijsenbeek, Gert-Jan Braunstahl, Jason O. Loekabino, Anne-Marie C. Dingemans, Johannes C. C. M. In't Veen, Catharina C. Moor

Summary: The study used eNose technology to analyze patients' breath profiles and found that the breath of ILD patients was significantly different from patients with other respiratory diseases, indicating high potential for accurately distinguishing ILD patients with this technology.

RESPIRATORY RESEARCH (2023)

No Data Available